FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Watt Christopher 2. Date of Event Requiring Statement (Month/Day/Year) 03/16/2018 3. Issuer Name and Ticker or Trading Symbol TETRAPHASE PHARMACEUTICALS INC [TTPH] (Last) (First) (Middle) C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, Finance 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) WATERTOWN, MA 02472 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 19,114 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Options (Right to Buy)	  (1)	07/14/2025	Common Stock	50,000	$ 50.49	D	Â
Employee Stock Option (Right to Buy)	  (2)	01/05/2026	Common Stock	25,000	$ 8.47	D	Â
Employee Stock Option (Right to Buy)	  (3)	01/29/2027	Common Stock	60,000	$ 3.69	D	Â
Employee Stock Option (Right to Buy)	  (4)	01/16/2028	Common Stock	50,000	$ 6.24	D	Â
Restricted Stock Units	  (5)	  (5)	Common Stock	12,500	$ (6)	D	Â
Restricted Stock Units	  (7)	  (7)	Common Stock	15,000	$ (6)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Watt Christopher C/O TETRAPHASE PHARMACEUTICALS, INC. 480 ARSENAL STREET, SUITE 110 WATERTOWN, MA 02472	Â	Â	  SVP, Finance	Â

Signatures

/s/Maria Stahl as Attorney-in-Fact for Christopher Watt		03/20/2018
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option vests over four years. Twenty-five percent (25%)of the shares vested on July 15, 2016 and 6.25% of the shares will vest at the end of each successive three month period thereafter.
(2)	Vests as to 6.25% of the shares on 4/6/2016 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/6/2020.
(3)	Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021.
(4)	Vests as to 6.25% of the shares on 4/17/2018 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/17/2022.
(5)	The restricted stock units vest in three equal installments on each of January 6, 2017, January 6, 2018 and January 6, 2019.
(6)	Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
(7)	These restricted stock units shall be earned upon achievement of certain performance conditions and, if earned, shall vest on January 31, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.